ondansetron has been researched along with Chronic Illness in 12 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 9.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Seventeen patients with severe pruritus complicating established chronic liver disease were randomized to receive, double-blind, ondansetron (8 mg) or a placebo orally; each was administered thrice daily for a 4-week period." | 9.12 | Ondansetron and pruritus in chronic liver disease: a controlled study. ( Jones, EA; Molenaar, HA; Oosting, J, 2007) |
| "Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus." | 9.08 | Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. ( Ferenci, P; Kaider, A; Müller, C; Penner, E; Pidlich, J; Pongratz, S; Raderer, M; Scheithauer, W; Schemper, M, 1998) |
| "When treating nausea in patients with chronic gastrointestinal syndromes, clinicians may consider trying higher performing treatments first, and forgoing lower performing treatments." | 5.56 | Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea. ( Clarke, JO; Fernandez-Becker, N; Garcia, M; Garcia, P; Grewal, D; Kamal, A; Nandwani, M; Neshatian, L; Nguyen, L; Okafor, P; Regalia, K; Sonu, I; Triadafilopoulos, G; Zikos, TA, 2020) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 5.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Seventeen patients with severe pruritus complicating established chronic liver disease were randomized to receive, double-blind, ondansetron (8 mg) or a placebo orally; each was administered thrice daily for a 4-week period." | 5.12 | Ondansetron and pruritus in chronic liver disease: a controlled study. ( Jones, EA; Molenaar, HA; Oosting, J, 2007) |
| "Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus." | 5.08 | Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. ( Ferenci, P; Kaider, A; Müller, C; Penner, E; Pidlich, J; Pongratz, S; Raderer, M; Scheithauer, W; Schemper, M, 1998) |
| "When treating nausea in patients with chronic gastrointestinal syndromes, clinicians may consider trying higher performing treatments first, and forgoing lower performing treatments." | 1.56 | Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea. ( Clarke, JO; Fernandez-Becker, N; Garcia, M; Garcia, P; Grewal, D; Kamal, A; Nandwani, M; Neshatian, L; Nguyen, L; Okafor, P; Regalia, K; Sonu, I; Triadafilopoulos, G; Zikos, TA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Suhas, S | 1 |
| Malo, PK | 1 |
| Kumar, V | 1 |
| Issac, TG | 1 |
| Chithra, NK | 1 |
| Bhaskarapillai, B | 1 |
| Reddy, YCJ | 1 |
| Rao, NP | 1 |
| Zikos, TA | 1 |
| Nguyen, L | 1 |
| Kamal, A | 1 |
| Fernandez-Becker, N | 1 |
| Regalia, K | 1 |
| Nandwani, M | 1 |
| Sonu, I | 1 |
| Garcia, M | 1 |
| Okafor, P | 1 |
| Neshatian, L | 1 |
| Grewal, D | 1 |
| Garcia, P | 1 |
| Triadafilopoulos, G | 1 |
| Clarke, JO | 1 |
| Akhondzadeh, S | 1 |
| Mohammadi, N | 1 |
| Noroozian, M | 1 |
| Karamghadiri, N | 1 |
| Ghoreishi, A | 1 |
| Jamshidi, AH | 1 |
| Forghani, S | 1 |
| Johnson, BA | 1 |
| Song, MY | 1 |
| Ku, SK | 1 |
| Kim, HJ | 1 |
| Han, JS | 1 |
| Zhang, ZJ | 1 |
| Kang, WH | 1 |
| Li, Q | 1 |
| Wang, XY | 1 |
| Yao, SM | 1 |
| Ma, AQ | 1 |
| Frigon, C | 1 |
| Desparmet, J | 1 |
| Jones, EA | 1 |
| Molenaar, HA | 1 |
| Oosting, J | 1 |
| Trioche, P | 1 |
| Samuel, D | 1 |
| Odièvre, M | 1 |
| Labrune, P | 1 |
| Briskin, JK | 1 |
| Curtis, JL | 1 |
| Müller, C | 1 |
| Pongratz, S | 1 |
| Pidlich, J | 1 |
| Penner, E | 1 |
| Kaider, A | 1 |
| Schemper, M | 1 |
| Raderer, M | 1 |
| Scheithauer, W | 1 |
| Ferenci, P | 1 |
| Kiss, A | 1 |
2 reviews available for ondansetron and Chronic Illness
| Article | Year |
|---|---|
Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials.
Topics: Adult; Aripiprazole; Child; Chronic Disease; Humans; Network Meta-Analysis; Obsessive-Compulsive Dis | 2023 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; | 2010 |
4 trials available for ondansetron and Chronic Illness
| Article | Year |
|---|---|
Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Cognition Disorders; Double-Blin | 2009 |
Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Diagnostic and Statistical Manual of | 2006 |
Ondansetron and pruritus in chronic liver disease: a controlled study.
Topics: Adolescent; Adult; Aged; Antipruritics; Chronic Disease; Double-Blind Method; Female; Humans; Liver | 2007 |
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; | 1998 |
6 other studies available for ondansetron and Chronic Illness
| Article | Year |
|---|---|
Marijuana, Ondansetron, and Promethazine Are Perceived as Most Effective Treatments for Gastrointestinal Nausea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Cannabis; Chronic Disease; Comparative Effe | 2020 |
Low molecular weight fucoidan ameliorating the chronic cisplatin-induced delayed gastrointestinal motility in rats.
Topics: Animals; Antineoplastic Agents; Antioxidants; Chronic Disease; Cisplatin; Enterochromaffin Cells; Ga | 2012 |
Ondansetron treatment in a child presenting with chronic intractable pruritus.
Topics: Antipruritics; Child; Chronic Disease; Humans; Male; Ondansetron; Pruritus | 2006 |
Ondansetron for pruritus in child with chronic cholestasis.
Topics: Alagille Syndrome; Child, Preschool; Cholestasis; Chronic Disease; Female; Humans; Ondansetron; Prur | 1996 |
Augmentation of clozapine therapy with ondansetron.
Topics: Adult; Animals; Chronic Disease; Clozapine; Drug Synergism; Drug Therapy, Combination; Humans; Male; | 1997 |
Treatment of chronic bulimic symptoms: new answers, more questions.
Topics: Antiemetics; Bulimia; Chronic Disease; Female; Follow-Up Studies; Humans; Ondansetron; Serotonin Ant | 2000 |